glp3.wiki

Weight Loss Drug Profiles: Every GLP-1 and GLP3 Agonist

Profiles of every major weight loss drug we track.

Look up a generic name or brand, check its formulation and status, then open the profile for sources and detailed reading.

Drug names, formulations and status

Approval is specific to a product, indication and country. Two brands containing the same drug may have different approved uses. Each profile links to the evidence behind its status.

9 drug profiles

  • Tirzepatide →

    Brand / other name: Zepbound, Mounjaro

    Formulation and route
    Once-weekly subcutaneous injection
    Development / approval status
    FDA-approved (Zepbound for weight loss, Mounjaro for type 2 diabetes)
    Mechanism
    Dual agonist — GLP-1 + GIP receptors

  • Semaglutide →

    Brand / other name: Wegovy, Ozempic, Rybelsus

    Formulation and route
    Once-weekly subcutaneous injection (Wegovy/Ozempic); once-daily oral tablet (Rybelsus; Wegovy pill approved Dec 2025)
    Development / approval status
    FDA-approved
    Mechanism
    GLP-1 receptor agonist

  • Orforglipron (Foundayo) →

    Brand / other name: Foundayo

    Formulation and route
    Once-daily oral pill — no food or water restrictions
    Development / approval status
    FDA-approved April 2026 — first non-peptide oral GLP-1 agonist
    Mechanism
    GLP-1 receptor agonist (non-peptide small molecule)

  • CagriSema →

    Brand / other name: cagrilintide + semaglutide

    Formulation and route
    Once-weekly subcutaneous injection
    Development / approval status
    NDA filed December 2025 — regulatory decision expected 2026
    Mechanism
    GLP-1 + amylin (fixed-dose combination)

  • Cagrilintide →

    No brand name listed

    Formulation and route
    Once-weekly subcutaneous injection
    Development / approval status
    Phase 3 — commercialized as half of CagriSema
    Mechanism
    Long-acting amylin receptor agonist

  • Mazdutide (Xinermei) →

    Brand / other name: Xinermei

    Formulation and route
    Once-weekly subcutaneous injection
    Development / approval status
    Approved in China (Xinermei) 2025; US Phase 2 ongoing
    Mechanism
    Dual agonist — GLP-1 + glucagon receptors

  • Survodutide →

    Brand / other name: BI 456906

    Formulation and route
    Once-weekly subcutaneous injection
    Development / approval status
    Phase 3 for obesity and MASH
    Mechanism
    Dual agonist — GLP-1 + glucagon receptors

  • Amycretin (zenagamtide) →

    Brand / other name: zenagamtide

    Formulation and route
    Once-daily oral tablet OR once-weekly subcutaneous injection
    Development / approval status
    Phase 3 for obesity initiated Q1 2026
    Mechanism
    Unimolecular GLP-1 + amylin dual agonist

  • Pemvidutide →

    Brand / other name: ALT-801

    Formulation and route
    Once-weekly subcutaneous injection
    Development / approval status
    Phase 2; FDA Breakthrough Therapy for MASH (Jan 2026); Phase 3 MASH planned
    Mechanism
    Balanced 1:1 GLP-1 + glucagon dual agonist

Choosing between treatments? Start with the comparison directory or the treatment-choice framework.

Browse drugs

7 articles